ArticleCancer chemotherapy and pharmacology2012

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.

Yoshitaka Seki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.